The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 08, 2016

Filed:

Apr. 30, 2012
Applicants:

Wiley Youngs, Akron, OH (US);

Matthew Panzner, Akron, OH (US);

Claire Tessier, Akron, OH (US);

Michael Deblock, Akron, OH (US);

Brian Wright, Akron, OH (US);

Patrick Wagers, Akron, OH (US);

Nikki Robishaw, Seville, OH (US);

Inventors:

Wiley Youngs, Akron, OH (US);

Matthew Panzner, Akron, OH (US);

Claire Tessier, Akron, OH (US);

Michael Deblock, Akron, OH (US);

Brian Wright, Akron, OH (US);

Patrick Wagers, Akron, OH (US);

Nikki Robishaw, Seville, OH (US);

Assignee:

The University of Akron, Akron, OH (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 235/02 (2006.01); C07D 235/04 (2006.01); C07D 233/58 (2006.01); C07D 233/60 (2006.01); C07D 233/68 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 405/06 (2006.01); C07D 487/04 (2006.01); C07D 403/14 (2006.01); C07D 473/08 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); C07D 233/58 (2013.01); C07D 233/60 (2013.01); C07D 233/68 (2013.01); C07D 235/02 (2013.01); C07D 235/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/06 (2013.01); C07D 473/08 (2013.01); C07D 487/04 (2013.01);
Abstract

Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplatin.


Find Patent Forward Citations

Loading…